We are live on ! Find out more
Daiwa Securities Group

Daiwa Securities Group Portfolio holdings

AUM $34.8B
1-Year Est. Return 20.7%
This Fund
S&P 500
This Quarter Est. Return
+7.46%
1 Year Est. Return
+20.7%
3 Year Est. Return
+66.64%
5 Year Est. Return
+79.21%
10 Year Est. Return
+192.59%
AUM
$29.6B
AUM Growth
+$2.54B
Cap. Flow
+$740M
Cap. Flow %
2.5%
Top 10 Hldgs %
36.41%
Holding
1,385
New
83
Increased
652
Reduced
368
Closed
52

Top Buys

Rank Stock Value
1
CRWD icon
CrowdStrike
CRWD
+$163M
2
NOW icon
ServiceNow
NOW
+$139M
3
ELS icon
Equity Lifestyle Properties
ELS
+$137M
4
CCI icon
Crown Castle
CCI
+$118M
5
NFLX icon
Netflix
NFLX
+$115M

Sector Composition

Rank Sector Weight
1 Technology 30%
2 Real Estate 28.67%
3 Communication Services 10.86%
4 Consumer Discretionary 6.91%
5 Financials 5.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ELVN icon
1226
Enliven Therapeutics
ELVN
$3.84B
$3K ﹤0.01%
152
FTRE icon
1227
Fortrea Holdings
FTRE
$1.96B
$3K ﹤0.01%
328
GERN icon
1228
Geron
GERN
$930M
$3K ﹤0.01%
2,247
KURA icon
1229
Kura Oncology
KURA
$826M
$3K ﹤0.01%
297
MGTX icon
1230
MeiraGTx Holdings
MGTX
$1.09B
$3K ﹤0.01%
330
DFTX
1231
Definium Therapeutics
DFTX
$5.57B
$3K ﹤0.01%
242
ORIC icon
1232
Oric Pharmaceuticals
ORIC
$1.23B
$3K ﹤0.01%
249
PHAT icon
1233
Phathom Pharmaceuticals
PHAT
$930M
$3K ﹤0.01%
260
PRAX icon
1234
Praxis Precision Medicines
PRAX
$8.25B
$3K ﹤0.01%
62
PSNL icon
1235
Personalis
PSNL
$1.27B
$3K ﹤0.01%
400
RLAY icon
1236
Relay Therapeutics
RLAY
$3.99B
$3K ﹤0.01%
486
SANA icon
1237
Sana Biotechnology
SANA
$916M
$3K ﹤0.01%
767
SYRE icon
1238
Spyre Therapeutics
SYRE
$8.68B
$3K ﹤0.01%
206
TBPH icon
1239
Theravance Biopharma
TBPH
$875M
$3K ﹤0.01%
215
TNGX icon
1240
Tango Therapeutics
TNGX
$4.34B
$3K ﹤0.01%
355
TRVI icon
1241
Trevi Therapeutics
TRVI
$2.62B
$3K ﹤0.01%
305
URGN icon
1242
UroGen Pharma
URGN
$1.99B
$3K ﹤0.01%
160
XERS icon
1243
Xeris Biopharma Holdings
XERS
$1.42B
$3K ﹤0.01%
404
XNCR icon
1244
Xencor
XNCR
$1.48B
$3K ﹤0.01%
222
ABSI icon
1245
Absci
ABSI
$1.21B
$2K ﹤0.01%
600
ARCT icon
1246
Arcturus Therapeutics
ARCT
$163M
$2K ﹤0.01%
90
ARVN icon
1247
Arvinas
ARVN
$529M
$2K ﹤0.01%
252
CMPS
1248
Compass Pathways
CMPS
$1.46B
$2K ﹤0.01%
327
CRMD icon
1249
CorMedix
CRMD
$577M
$2K ﹤0.01%
200
CSTL icon
1250
Castle Biosciences
CSTL
$725M
$2K ﹤0.01%
86

Similar funds

Daiwa Securities Group's Q3 2025 Portfolio in Review

As of Q3 2025, Daiwa Securities Group held 1,385 positions worth $29.6B, up 9.4% from $27.1B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Daiwa Securities Group's Q3 2025 filing shows 83 new, 652 increased, 368 reduced and 52 closed positions. Its largest new stake was Eagle Materials: 54,795 shares worth $12.8M. The largest sale was Global X Conscious Companies ETF, an estimated $130M.

By sector, the portfolio is most concentrated in Technology at 30% of assets, up from 28% a quarter earlier, followed by Real Estate and Communication Services.

  • Daiwa Securities Group's largest Q3 2025 buy was Eagle Materials: 54,795 shares worth $12.8M.
  • Daiwa Securities Group added most to CrowdStrike in Q3 2025, an estimated $163M increase.
  • Daiwa Securities Group's biggest Q3 2025 reduction was Global X Conscious Companies ETF, cutting an estimated $130M.
  • Daiwa Securities Group fully exited Ansys in Q3 2025, selling an estimated $6.94M.
  • Daiwa Securities Group's ten largest holdings make up 36% of its $29.6B portfolio in Q3 2025.
  • Daiwa Securities Group opened 83 new positions and closed 52 in Q3 2025.
  • Daiwa Securities Group's portfolio value rose 9.4% quarter-over-quarter to $29.6B.

Based on Daiwa Securities Group's 13F filing for Q3 2025, filed 14 Nov 2025.